Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06495593 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06495593 · ClinicalTrials.gov record · last posted 2026-03-27

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Study acronym: OCREFINA
StatusEnrolling by Invitation
PhasePhase 4
Started2025-02-04
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
B cell-depleting therapies, such as ocrelizumab, are among the most effective medications currently available for the treatment of multiple sclerosis (MS). This suggests that B cells play a very important role in MS. While B cells are rapidly eliminated from the blood of patients treated with medications like ocrelizumab, little is known about how effectively B cells are eliminated from lymph nodes, which are important sites of B cell activation. This study is being conducted to determine to what extent B cells are targeted in lymph nodes following ocrelizumab treatment, which may have important consequences for long-term MS outcomes.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2024-07-03; most recent amendment 2026-03-23. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-03-23
Status change Recruiting→Enrolling by Invitationv3
2025-02-10
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT06495593
Lead Sponsor University of California, San Francisco
Collaborators: Genentech, Inc.
Conditions Multiple Sclerosis, Relapsing-Remitting
Enrollment 5 participants
Start Date 2025-02-04
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-27